Malcolm Brenner, MD, PhD

Full Affiliate Member, Research Institute
Houston Methodist


Dr. Brenner completed his postdoctoral training in 1981 and joined the Clinical Research Centre of Northwick Park Hospital in London, England as a MRC Clinical Scientist and Honorary Senior Registrar. He also began lecturing in Haematology at the Royal Free Hospital and Hospital for Sick Children, also in London.

Dr. Brenner joined the faculty at the University of Tennessee in Memphis as a Professor in the Departments of Pediatrics and Medicine in 1990. He also became the Director of the Bone Marrow Transplant Division of the St. Jude Children's Research Hospital that same year. He later directed the Cell and Gene Therapy Program at St. Jude's from 1994 until 1997, when he assumed his current positions at the Baylor College of Medicine.

Description of Research

Dr. Brenner's research focuses on gene transfer to stem cells and to effector cells of the immune system. His research group was one of the first to use gene transfer in human subjects, establishing the feasibility of tracking human stem cells and their progeny in subjects with cancer. Dr. Brenner also develops tumor vaccines for pediatric and hematological malignancies, using genetic modification with retroviral and adenoviral vectors.

Areas Of Expertise

Stem cells Gene therapy Cell therapy Vectors
Education & Training

PhD, Cambridge University

CAR T cell therapy for breast cancer: Harnessing the tumor milieu to drive T cell activation
Bajgain, P, Tawinwung, S, DElia, L, Sukumaran, S, Watanabe, N, Hoyos, V, Lulla, P, Brenner, MK, Leen, AM & Vera, JF 2018, Journal for ImmunoTherapy of Cancer, vol 6, no. 1, 34. DOI: 10.1186/s40425-018-0347-5

Onward and upward for immuno-oncology
Brenner, MK 2018, Chinese Clinical Oncology, vol 7, no. 2, 18. DOI: 10.21037/cco.2018.01.04

Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer
Rosewell Shaw, A, Porter, CE, Watanabe, N, Tanoue, K, Sikora, A, Gottschalk, S, Brenner, MK & Suzuki, M 2017, Molecular Therapy, vol 25, no. 11, pp. 2440-2451. DOI: 10.1016/j.ymthe.2017.09.010

Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation
Tzannou, I, Papadopoulou, A, Naik, S, Leung, K, Martinez, CA, Ramos, CA, Carrum, G, Sasa, G, Lulla, P, Watanabe, A, Kuvalekar, M, Gee, AP, Wu, MF, Liu, H, Grilley, BJ, Krance, RA, Gottschalk, S, Brenner, MK, Rooney, CM, Heslop, HE, Leen, AM & Omer, B 2017, Journal of Clinical Oncology, vol 35, no. 31, pp. 3547-3557. DOI: 10.1200/JCO.2017.73.0655

Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells
Shum, T, Omer, B, Tashiro, H, Kruse, RL, Wagner, DL, Parikh, K, Yi, Z, Sauer, T, Liu, D, Parihar, R, Castillo, P, Liu, H, Brenner, MK, Metelitsa, LS, Gottschalk, S & Rooney, CM 2017, Cancer Discovery, vol 7, no. 11, pp. 1238-1247. DOI: 10.1158/2159-8290.CD-17-0538

Next Steps in the CAR Journey of a Thousand Miles
Brenner, MK 2017, Molecular Therapy. DOI: 10.1016/j.ymthe.2017.09.013

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
Gomes-Silva, D, Mukherjee, M, Srinivasan, M, Krenciute, G, Dakhova, O, Zheng, Y, Cabral, JMS, Rooney, CM, Orange, JS, Brenner, MK & Mamonkin, M 2017, Cell Reports, vol 21, no. 1, pp. 17-26. DOI: 10.1016/j.celrep.2017.09.015

Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1
Tashiro, H, Sauer, T, Shum, T, Parikh, K, Mamonkin, M, Omer, B, Rouce, RH, Lulla, P, Rooney, CM, Gottschalk, S & Brenner, MK 2017, Molecular Therapy, vol 25, no. 9, pp. 2202-2213. DOI: 10.1016/j.ymthe.2017.05.024

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Ramos, CA, Ballard, B, Zhang, H, Dakhova, O, Gee, AP, Mei, Z, Bilgi, M, Wu, MF, Liu, H, Grilley, B, Bollard, CM, Chang, BH, Rooney, CM, Brenner, MK, Heslop, HE, Dotti, G & Savoldo, B 2017, Journal of Clinical Investigation, vol 127, no. 9, pp. 3462-3471. DOI: 10.1172/JCI94306

HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation trial
Ahmed, N, Brawley, V, Hegde, M, Bielamowicz, K, Kalra, M, Landi, D, Robertson, C, Gray, TL, Diouf, O, Wakefield, A, Ghazi, A, Gerken, C, Yi, Z, Ashoori, A, Wu, MF, Liu, H, Rooney, C, Dotti, G, Gee, A, Su, J, Kew, Y, Baskin, D, Zhang, YJ, New, P, Grilley, B, Stojakovic, M, Hicks, J, Powell, SZ, Brenner, MK, Heslop, HE, Grossman, R, Wels, WS & Gottschalk, S 2017, JAMA Oncology, vol 3, no. 8, pp. 1094-1101. DOI: 10.1001/jamaoncol.2017.0184

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
Gomes-Silva, D, Srinivasan, M, Sharma, S, Lee, CM, Wagner, DL, Davis, TH, Rouce, RH, Bao, G, Brenner, MK & Mamonkin, M 2017, Blood, vol 130, no. 3, pp. 285-296. DOI: 10.1182/blood-2017-01-761320

Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of Chimeric antigen receptor t cells in solid tumors
Tanoue, K, Shaw, AR, Watanabe, N, Porter, C, Rana, B, Gottschalk, S, Brenner, M & Suzuki, M 2017, Cancer Research, vol 77, no. 8, pp. 2040-2051. DOI: 10.1158/0008-5472.CAN-16-1577

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
Heczey, A, Louis, CU, Savoldo, B, Dakhova, O, Durett, A, Grilley, B, Liu, H, Wu, MF, Mei, Z, Gee, A, Mehta, B, Zhang, H, Mahmood, N, Tashiro, H, Heslop, HE, Dotti, G, Rooney, CM & Brenner, MK 2017, Molecular Therapy. DOI: 10.1016/j.ymthe.2017.05.012

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
Mohammed, S, Sukumaran, S, Bajgain, P, Watanabe, N, Heslop, HE, Rooney, CM, Brenner, MK, Fisher, WE, Leen, AM & Vera, JF 2017, Molecular Therapy, vol 25, no. 1, pp. 249-258. DOI: 10.1016/j.ymthe.2016.10.016

Immunotherapy against cancer-related viruses
Tashiro, H & Brenner, MK 2017, Cell Research, vol 27, no. 1, pp. 59-73. DOI: 10.1038/cr.2016.153

Fine-tuning the CAR spacer improves T-cell potency
Watanabe, N, Bajgain, P, Sukumaran, S, Ansari, S, Heslop, HE, Rooney, CM, Brenner, MK, Leen, AM & Vera, JF 2016, OncoImmunology, vol 5, no. 12, e1253656. DOI: 10.1080/2162402X.2016.1253656

Improving the safety of T-Cell therapies using an inducible caspase-9 gene
Zhou, X & Brenner, MK 2016, Experimental Hematology, vol 44, no. 11, pp. 1013-1019. DOI: 10.1016/j.exphem.2016.07.011

Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape
Hegde, M, Mukherjee, M, Grada, Z, Pignata, A, Landi, D, Navai, SA, Wakefield, A, Fousek, K, Bielamowicz, K, Chow, KKH, Brawley, VS, Byrd, TT, Krebs, S, Gottschalk, S, Wels, WS, Baker, ML, Dotti, G, Mamonkin, M, Brenner, MK, Orange, JS & Ahmed, N 2016, Journal of Clinical Investigation, vol 126, no. 8, pp. 3036-3052. DOI: 10.1172/JCI83416

Clinical responses with T lymphocytes targeting malignancy-associated ? light chains
Ramos, CA, Savoldo, B, Torrano, V, Ballard, B, Zhang, H, Dakhova, O, Liu, E, Carrum, G, Kamble, RT, Gee, AP, Mei, Z, Wu, MF, Liu, H, Grilley, B, Rooney, CM, Brenner, MK, Heslop, H & Dotti, G 2016, Journal of Clinical Investigation, vol 126, no. 7, pp. 2588-2596. DOI: 10.1172/JCI86000

3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus
Del Bufalo, F, Manzo, T, Hoyos, V, Yagyu, S, Caruana, I, Jacot, J, Benavides, O, Rosen, D & Brenner, MK 2016, Biomaterials, vol 84, pp. 76-85. DOI: 10.1016/j.biomaterials.2016.01.030